SCHEDULE: Northstrive Fund II LP, Braeden Lichti Boost Bluejay Diagnostics Stake

Northstrive Fund II LP and its manager, Braeden Lichti, have disclosed significant beneficial ownership in Bluejay Diagnostics, Inc., with Lichti now holding over 5% of common stock.

Summary

• Northstrive Fund II LP and Braeden Lichti have filed a Schedule 13G, disclosing their beneficial ownership in Bluejay Diagnostics, Inc.
• Northstrive Fund II LP beneficially owns 11,000 shares, representing 1.55% of the common stock.
• Braeden Lichti, as an individual, beneficially owns 35,500 shares, representing 5.01% of the common stock.
• The percentage ownership calculations are based on 708,533 shares of Bluejay Diagnostics, Inc. common stock outstanding as of January 29, 2026.
• Braeden Lichti serves as the Manager of Northstrive Fund II LP.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant investor has increased their stake, potentially indicating confidence in the company's future prospects, although the filing itself provides no operational details.

Positives

• A significant investor, Braeden Lichti, has increased his beneficial ownership to 5.01% of Bluejay Diagnostics, Inc. common stock.
• Northstrive Fund II LP, managed by Mr. Lichti, holds an additional 1.55% beneficial ownership.

Negatives

• No negative information regarding Bluejay Diagnostics, Inc.'s operations or financial performance is disclosed in this beneficial ownership filing.

Risks

• No specific risks related to Bluejay Diagnostics, Inc. are detailed in this beneficial ownership disclosure.

Future Outlook

NA

Management Comments

• Braeden Lichti is the Manager of Northstrive Fund II LP.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for passive investors who acquire more than 5% of a company's stock, indicating a significant, non-controlling stake. This filing signals increased confidence from Northstrive Fund II LP and Braeden Lichti in Bluejay Diagnostics, Inc.

Stakeholder Impact

• Shareholders: The increased beneficial ownership by Northstrive Fund II LP and Braeden Lichti may be perceived as a vote of confidence, potentially influencing investor sentiment positively.

Next Steps

• No specific future actions or milestones are mentioned in this beneficial ownership filing.

Key Dates

Keywords

Bluejay Diagnostics, Northstrive Fund II LP, Braeden Lichti, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Stakeholder